Biocon's Pertuzumab gets EMA CHMP approval recommendation

Biocon's Pertuzumab gets EMA CHMP approval recommendation. This marks the first biosimilar to secure a positive opinion under the new tailored clinical approach. The approval paves the way for market entry in Europe, boosting revenue potential. Pertuzumab targets a multi-billion dollar oncology segment.

📊 STOCKS: $BIOCON | 🏢 SECTOR: Pharma | #HIGHIMPACT #BioSimilars